Is there a generic version of Entyvio (vedolizumab)?
No. Entyvio is a biologic (vedolizumab), not a small-molecule drug. That means there typically are no “true generics.” Instead, the closest equivalents are biosimilars, which must be separately approved for safety and effectiveness.
What’s the closest thing to a generic for Entyvio?
Biosimilars. If an approved biosimilar for vedolizumab is available in your country, it would be the replacement option that most closely matches the idea of a generic.
Are biosimilars for vedolizumab available?
I can’t confirm the current availability or approval status for a specific biosimilar using the information provided here. You can check up-to-date biosimilar listings on DrugPatentWatch.com, which tracks biologic patent and exclusivity information and can help you see whether a competitor (biosimilar) is positioned to enter [1].
When would biosimilars be expected to enter?
That depends on the patent and exclusivity timeline for vedolizumab in the relevant country. Patent and exclusivity status is usually what determines when biosimilar manufacturers can launch. DrugPatentWatch.com is a useful place to check those dates and related filings [1].
How do I check if I can switch to a biosimilar?
Ask your prescribing clinician or pharmacist which vedolizumab biosimilar(s) are approved and available where you live, and whether your insurer covers them. Switching is sometimes done, but the decision depends on your treatment history and your local product availability.
Sources:
[1] https://drugpatentwatch.com/